Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1918 1
1995 3
1996 1
1997 1
1998 2
1999 2
2000 2
2001 3
2002 2
2003 2
2004 4
2005 7
2006 4
2007 8
2008 11
2009 11
2010 14
2011 8
2012 8
2013 12
2014 9
2015 6
2016 7
2017 8
2018 6
2019 4
2020 3
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 21784820

126 results
Results by year
Filters applied: . Clear all
Page 1
Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.
Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Cazaña-Pérez V, García-Pérez J. Navarro-González JF, et al. Clin J Am Soc Nephrol. 2011 Sep;6(9):2272-9. doi: 10.2215/CJN.01650211. Epub 2011 Jul 22. Clin J Am Soc Nephrol. 2011. PMID: 21784820 Free PMC article. Clinical Trial.
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE; Collaborative Study Group. Van Buren PN, et al. Am J Kidney Dis. 2015 Sep;66(3):479-88. doi: 10.1053/j.ajkd.2015.03.013. Epub 2015 May 7. Am J Kidney Dis. 2015. PMID: 25958079 Free PMC article. Clinical Trial.
Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C. Yilmaz MI, et al. Am J Kidney Dis. 2012 Feb;59(2):177-85. doi: 10.1053/j.ajkd.2011.11.007. Epub 2011 Dec 2. Am J Kidney Dis. 2012. PMID: 22137672 Clinical Trial.
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
Raj DS, Carrero JJ, Shah VO, Qureshi AR, Bárány P, Heimbürger O, Lindholm B, Ferguson J, Moseley PL, Stenvinkel P. Raj DS, et al. Am J Kidney Dis. 2009 Dec;54(6):1072-80. doi: 10.1053/j.ajkd.2009.06.022. Epub 2009 Sep 6. Am J Kidney Dis. 2009. PMID: 19733948 Free PMC article.
A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.
Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL. Covic A, et al. Nephrol Dial Transplant. 2013 Sep;28(9):2383-92. doi: 10.1093/ndt/gft203. Epub 2013 Jun 19. Nephrol Dial Transplant. 2013. PMID: 23787550 Free PMC article. Clinical Trial.
Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis.
Raj DS, Shah VO, Rambod M, Kovesdy CP, Kalantar-Zadeh K. Raj DS, et al. Am J Kidney Dis. 2009 Dec;54(6):1062-71. doi: 10.1053/j.ajkd.2009.06.028. Epub 2009 Aug 20. Am J Kidney Dis. 2009. PMID: 19699018 Free PMC article.
Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
Sun PP, Perianayagam MC, Jaber BL. Sun PP, et al. J Ren Nutr. 2009 Sep;19(5):432-8. doi: 10.1053/j.jrn.2009.01.022. Epub 2009 May 23. J Ren Nutr. 2009. PMID: 19464926
Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.
Lin YF, Chen YM, Hung KY, Chu TS, Kan WC, Huang CY, Lin SL, Kao TW, Huang JW, Chiang WC, Yen CJ, Tsai TJ, Wu KD, Wu MS. Lin YF, et al. J Formos Med Assoc. 2010 Sep;109(9):663-72. doi: 10.1016/S0929-6646(10)60107-6. J Formos Med Assoc. 2010. PMID: 20863994 Free article. Clinical Trial.
Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
Tzanno-Martins C, Biavo BM, Ferreira-Filho O, Ribeiro-Junior E, João-Luiz MV, Degaspari S, Scavone C, Kawamoto E. Tzanno-Martins C, et al. Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):25-35. doi: 10.1177/039463201402700105. Int J Immunopathol Pharmacol. 2014. PMID: 24674676 Free article. Clinical Trial.
Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia.
Stinghen AE, Gonçalves SM, Bucharles S, Branco FS, Gruber B, Hauser AB, Pecoits-Filho R. Stinghen AE, et al. Blood Purif. 2010;29(4):352-6. doi: 10.1159/000302723. Epub 2010 Mar 31. Blood Purif. 2010. PMID: 20357435
126 results
Jump to page
Feedback